Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

International Multicentric Study ARON-1

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged \>18y - Cytological or diagnosed by tissue sample (biopsy-confirmed) diagnosis of clear cell or non-clear cell RCC - Histologically or radiologically confirmed diagnosis of metastatic disease - First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab Who Should NOT Join This Trial: - Patients without diagnosed by tissue sample (biopsy-confirmed) diagnosis of RCC - Patients without histologically or radiologically confirmed metastatic disease - Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged \>18y * Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC * Histologically or radiologically confirmed diagnosis of metastatic disease * First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab Exclusion Criteria: * Patients without histologically confirmed diagnosis of RCC * Patients without histologically or radiologically confirmed metastatic disease * Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section

Treatments Being Tested

DRUG

pembrolizumab plus axitinib

collect global experiences with the use of immuno-combinations in patients with metastatic RCC

Locations (1)

Ospedale di Macerata, UOC Oncologia
Macerata, Macerata, Italy